Roche is moving forward with trials that combine Tecentriq, its cancer immunotherapy drug, with other drugs after early data suggested positive outcomes.
Two of the studies are moving into phase III late-stage pivotal trials. One combined Tecentriq with Cotellic and Zelboraf in 30 patients with untreated BRAFV600 mutation-positive metastatic melanoma. Another combined Tecentriq with Cotellic for 10 patients with BRAF-wild-type and BRAF-mutant metastatic melanoma.
The drug was previously projected to bring the company $3 billion by 2020 according to Bloomberg.This comes as good news for Roche as its recent hemophilia drug stumbled in trials.
Read the Reuters report